A Study Comparing postoperative pain relief in knee surgery

COMPARISON OF EFFICACY BETWEEN TRANSDERMAL DICLOFENAC PATCH VS CONVENTIONAL INTRAVENOUS ANALGESICS IN ARTHROSCOPIC ACL RECONSTRUCTION - A PROSPECTIVE RANDOMISED CONTROL TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112797

Enrollment

Registered

2026-06-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M968- Other intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified

Interventions

Intervention1: DICLOFENAC PATCH: DICLOFENAC PATCH FOR THE POST OPERATIVE PAIN MANAGEMENT FOR THE ARTHROSCOPIC PAIN MANAGEMENT Control Intervention1: CONVENTIONAL INTRAVENOUS ANALGESICS: CONVENTIONAL I

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1 Patients aged 18 to 65 years undergoing arthroscopic knee surgery for MRI-confirmed ACL or PCL injury with or without associated meniscal injury 2 Patients willing to participate and provide informed consent 3 Patients undergoing surgery under spinal anaesthesia with regional/femoral block (diclofenac group) 4 Patients undergoing combined epidural and spinal anaesthesia (conventional group)

Exclusion criteria

Exclusion criteria: Exclusion Criteria 1 Severe renal or hepatic impairment. 2 History of peptic ulcer disease or gastrointestinal bleeding 3 Chronic opioid use 4 NSAID hypersensitivity 5 Poly-ligamentous knee injury/surgery cases 6 Polytrauma patients 7 Patients with head injury

Design outcomes

Primary

Measure	Time frame
TO Compare the Analgesic Efficacy of Diclofenac Transdermal patch with Conventional Intravenous Analgesics in Post-operative pain management of patients Undergoing Arthroscopic ACL reconstruction surgeryTimepoint: 52 weeks	—

Secondary

Measure	Time frame
To assess the safety profile of both analgesics in terms of adverse effectTimepoint: 52 WEEKS	—

Countries

India

Contacts

Public ContactANOOP K V

KAHER INSTITUTE Belagavi Karnataka 590010

anoopkaimara@gmail.com9113878291

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026